Hosted on MSN27d
Patisiran Shows Long-Term Benefit in Hereditary ATTR With Polyneuropathy
Long-term treatment with patisiran (Onpattro) led to modest changes for people with hereditary transthyretin amyloidosis (hATTR) with polyneuropathy, data from a global open-label extension (OLE ...
凯莱英取得一种Patisiran的制备方法专利
金融界2025年1月28日消息，国家知识产权局信息显示，凯莱英医药集团（天津）股份有限公司取得一项名为“一种Patisiran的制备方法”的专利，授权公告号CN 118460647 B，申请日期为2024年7月。
pharmaphorum1d
Alnylam beats Ionis in RNA drug battle
Alnylam and Sanofi have revealed full phase 3 data on their RNA interference (RNAi) drug patisiran, soundly beating a rival candidate from Ionis, inotersen. Both drugs target hereditary ATTR ...
证券之星14d
凯莱英获得发明专利授权：“一种Patisiran的制备方法”
证券之星消息，根据天眼查APP数据显示凯莱英（002821）新获得一项发明专利授权，专利名为“一种Patisiran的制备方法”，专利申请号为CN202410921727.7 ...
MedPage Today28d
Patisiran Shows Long-Term Benefit in Hereditary ATTR With Polyneuropathy
Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Patisiran continued to demonstrate benefit in hATTR with polyneuropathy at 5 years. Measures of disability ...